From what 0 stock analysts predict, the share price for Senti Biosciences, Inc. (SNTI) might decrease by 100% in the next year. This is based on a 12-month average estimation for SNTI. Price targets go from $ to $. The majority of stock analysts believe SNTI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned SNTI 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Senti Biosciences, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on SNTI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of SNTI.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Geulah Livshits Chardan Capital | Buy | $6 | Reiterates | Aug 15, 2023 |
Geulah Livshits Chardan Capital | Buy | $6 | Maintains | May 11, 2023 |
Michael Ulz Morgan Stanley | Equal-Weight | $2 | Maintains | Mar 24, 2023 |
Geulah Livshits Chardan Capital | Buy | $7 | Maintains | Mar 23, 2023 |
Geulah Livshits Chardan Capital | Buy | $8 | Maintains | Jan 30, 2023 |
Michael Ulz Morgan Stanley | Equal-Weight | $3 | Maintains | Jan 27, 2023 |
Brian Cheng JP Morgan | Neutral | Initiates | Dec 16, 2022 | |
Michael Ulz Morgan Stanley | Equal-Weight | $7.5 | Initiates | Oct 7, 2022 |
Greg Harrison B of A Securities | Buy | $7 | Initiates | Sep 29, 2022 |
Geulah Livshits Chardan Capital | Buy | $12 | Initiates | Sep 23, 2022 |
When did it IPO
2021
Staff Count
48
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Timothy K. Lu M.D., Ph.D.
Market Cap
$12.4M
In 2023, SNTI generated $2.0M in revenue, which was a decrease of -39.81% from the previous year. This can be seen as a signal that SNTI's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.